Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.
How are current events in drug development demanding better enteric delivery solutions, and how is material science and manufacturing innovation creating a purpose-built capsule able to go the distance – all while reducing the cost and complexity of enteric development and delivery?
MUPS formulations are a widely used pharmaceutical dosage form for esomeprazole, a proton pump inhibitor. For this purpose, micropellets are coated with the active ingredient and administered in the form of tablets or capsules. An appropriate solution for the coating of micropellets is the use of fluid bed processors which utilise air flow bed technology
Since their introduction in 1956, pressurised metered dose inhalers (pMDIs) have become the dominant treatment choice for patients suffering from common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). However, unbeknown to most patients and many doctors, pMDIs account for 3.9% of NHS’s annual carbon emissions.1 Here we will discuss how formulation changes might be the answer to the pMDI-related sustainability problem
Ensuring pharma products are manufactured in a safe and controlled way is a priority. How can the industry ensure that this happens?
Bioprinted products are already starting to demonstrate life-changing potential, but the path to commercialisation is complex, requiring developers to better understand the factors that impact regulatory classification
IPT sat down with Dr Chris Vincent at PDD, to understand more about the digital innovations that are leading design and whether technologies like Extended Reality (XR) can be beneficial to the process
As technology within the analysis sphere continues to evolve, temperature control is becoming increasingly important for drug discovery and research
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. How best can they be implemented?